Labiotech.eu

Opinion 24 Oct 2022

Hiding in plain sight: how to solve bioscience’s software problem

Guy Levy-Yurista, CEO of the experiment platform developer Synthace, gives his take on what’s missing in increasingly software-dependent life sciences labs: a holistic mindset for improving experimental methods. There’s a major problem holding back progress in biotech, and more widely in the life sciences. It’s not an obvious one, but based on the conversations I […]

October 24, 2022 - 5 minutesmins - By External Contributor

News and Trends 21 Oct 2022

Watch: NLS Days NLSInvest award winners – MyoPax

The two biotech start-up companies MyoPax and Asgards Therapeutics won first and second prize at NLSINvest Awards, out of 40 companies that participated in Nordic Life Science Days’ start-up pitching challenge. 40 selected Nordic start-up companies attended Nordic Life Science Days, the largest partnering conference for life sciences in the Nordics, in Malmö. As part […]

October 21, 2022 - 2 minutesmins - By Jim Cornall

News and Trends 21 Oct 2022

Beyond Biotech podcast 19: Bone Health Technologies, Immutep, TAU Systems

This week, we have three guests. We have conversations with Marc Voigt, CEO of Immutep; Manuel Hegelich, CEO of TAU Systems; and Laura Yecies, CEO of Bone Health Technologies. We also have our weekly chat with global commercial real estate services company JLL, with Travis McCready. FDA fast tracks Immutep non-small cell lung cancer candidate […]

October 21, 2022

Inside Labiotech 21 Oct 2022

Meet Bárbara, our new sales representative

We’re very excited to welcome Bárbara to our team! She will be working with us to help the biopharma and biotech industries connect and grow. Let’s take a look at why she decided to join us and her ambitions with Labiotech. Bárbara Leite, Sales Representative From Porto, Portugal Bárbara, to start with, how would you […]

October 21, 2022 - 3 minutesmins - By Yi-Jen Chang

News and Trends 20 Oct 2022

Sunshine Biopharma acquires Nora Pharma

Sunshine Biopharma Inc, a pharmaceutical company focused on the research, development and commercialization of oncology and antiviral drugs, has completed the acquisition of all the outstanding shares of Nora Pharma Inc., effective immediately. Nora Pharma is now a wholly owned subsidiary of Sunshine Biopharma Inc. The addition of Nora Pharma allows Sunshine Biopharma to expand […]

October 20, 2022 - 3 minutesmins - By Jim Cornall

In Depth 20 Oct 2022

Opportunities and challenges for cell and gene therapy investments

Companies in the cell and gene therapy space are struggling to raise investments amid adverse market conditions. However, this could be an opportunity for the strongest companies and investors to shine. After several years of record-breaking investments, funding is hard to come by in the gene and cell therapy space. Part of this trend relates […]

October 20, 2022 - 9 minutesmins - By Jonathan Smith

News and Trends 20 Oct 2022

Tiziana Life Sciences looks to phase 1 trial for intranasal Alzheimer’s drug

Tiziana Life Sciences Ltd. says it plans to submit an investigational new drug (IND) application for a phase 1 trial of intranasal foralumab in Alzheimer’s disease patients. It comes after the company received an affirmative written response from the FDA on a pre-investigational new drug application (PIND). Tiziana plans on filing the IND for Alzheimer’s […]

October 20, 2022 - 3 minutesmins - By Jim Cornall

News and Trends 20 Oct 2022

Spanish research institution to use Elicera Therapeutics’ iTANK platform

Elicera Therapeutics AB has entered a material transfer agreement with the Josep Carreras Leukaemia Research Institute (JCLRI) in Spain for use of the iTANK platform in arming CAR T-cells for the treatment of Ewing Sarcoma. Sweden’s Elicera is a clinical stage cell and gene therapy company developing next generation immuno-oncological treatments based on enhanced oncolytic […]

October 20, 2022 - 3 minutesmins - By Jim Cornall

News and Trends 20 Oct 2022

AbbVie acquires LifeArc portfolio company DJS Antibodies

AbbVie has acquired LifeArc’s portfolio company DJS Antibodies Limited, a privately-held UK-based biotechnology company dedicated to discovering and developing antibody medicines that target difficult-to-drug disease-causing proteins, such as G protein-coupled receptors (GPCRs). DJS’s lead program is DJS-002, a potential first-in-class lysophosphatidic acid (LPA) receptor 1 (LPAR1) antagonist antibody currently in investigational preclinical studies for the […]

October 20, 2022 - 3 minutesmins - By Jim Cornall

News and Trends 20 Oct 2022

Partnership formed to make drug for MoCD Type A available sooner

Inceptua Early Access and Sentynl Therapeutics Inc., a U.S.-based biopharmaceutical company bringing therapies to patients living with rare diseases, have entered into a partnership. The partnership is to make Sentynl’s Nulibry available via an early access program for eligible patients with molybdenum cofactor deficiency (MoCD) Type A. MoCD Type A is a rapidly progressive autosomal […]

October 20, 2022 - 2 minutesmins - By Liza Laws

brain cancer glioblastoma divide and conquer

News and Trends 20 Oct 2022

Healthy volunteer study for tablet to treat brain cancer open for recruitment

A clinical stage drug company developing sulforaphane-based medicines for cancer treatment has started recruiting for a pharmacokinetic / pharmacodynamic trial in healthy volunteers (HV). Evgen Pharma plc also announced the start an investigator sponsored clinical study (ISS) for a glioblastoma program. The purpose of the HV study is to examine the performance of Evgen’s new […]

October 20, 2022 - 4 minutesmins - By Liza Laws

News and Trends 20 Oct 2022

Alvotech and JAMP Pharma add two biosimilar candidates for Canadian market

Alvotech and the JAMP Pharma Group have expanded their exclusive partnership to commercialize biosimilars developed and manufactured by Alvotech. The companies have added two biosimilar candidates from Alvotech’s pipeline: AVT16, a proposed biosimilar to an undisclosed immunology product and AVT33, a proposed biosimilar to an undisclosed oncology product. “We are very pleased to be expanding […]

October 20, 2022 - 2 minutesmins - By Jim Cornall

Knowledge hub

Categories

Illuminating biotech in the City of Light: Inside Paris’s thriving ecosystem

ASCO 2025: key highlights in cancer therapeutics

Approaches

Therapeutic areas

New report: Artificial intelligence and the future of antibody discovery

Stem cell therapy: a potential cure for hearing loss?

R&D

BD

World biotech leaders

Connect with decision-makers and researchers worldwide for collaborative opportunities

Company

Join Us

Subscribe to our newsletter

Advertise with us

Illuminating biotech in the City of Light: Inside Paris’s thriving ecosystem

ASCO 2025: key highlights in cancer therapeutics

New report: Artificial intelligence and the future of antibody discovery

Stem cell therapy: a potential cure for hearing loss?

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

Hiding in plain sight: how to solve bioscience’s software problem

Watch: NLS Days NLSInvest award winners – MyoPax

Beyond Biotech podcast 19: Bone Health Technologies, Immutep, TAU Systems

Meet Bárbara, our new sales representative

Sunshine Biopharma acquires Nora Pharma

Opportunities and challenges for cell and gene therapy investments

Tiziana Life Sciences looks to phase 1 trial for intranasal Alzheimer’s drug

Spanish research institution to use Elicera Therapeutics’ iTANK platform

AbbVie acquires LifeArc portfolio company DJS Antibodies

Partnership formed to make drug for MoCD Type A available sooner

Healthy volunteer study for tablet to treat brain cancer open for recruitment

Alvotech and JAMP Pharma add two biosimilar candidates for Canadian market

Subscribe to our newsletter to get the latest biotech news!

Illuminating biotech in the City of Light: Inside Paris’s thriving ecosystem

ASCO 2025: key highlights in cancer therapeutics

New report: Artificial intelligence and the future of antibody discovery

Stem cell therapy: a potential cure for hearing loss?

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

Illuminating biotech in the City of Light: Inside Paris’s thriving ecosystem

ASCO 2025: key highlights in cancer therapeutics

New report: Artificial intelligence and the future of antibody discovery

Stem cell therapy: a potential cure for hearing loss?

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

Subscribe to our newsletter

Get the latest biotech news directly to your inbox!

Newsletter Signup - Footer

Subscribe to our newsletter to get the latest biotech news!